Efficacy of baricitinib in severe coronavirus disease 2019
Background Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with the intracellular signaling pathway of many cyt...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Egyptian Journal of Chest Disease and Tuberculosis |
| Subjects: | |
| Online Access: | http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2023;volume=72;issue=3;spage=355;epage=357;aulast=Amer |